Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
17464
¥ million (year-on-year increase in FY2026 revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFiscal year ending March 2026, full year10 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥158,535 million+5.2%
Operating profit¥11,054 million+9.3%
Ordinary income¥12,303 million+18.7%
Net income¥7,707 million +18.0%net profit attributable to owners of the parent
Operating profit margin7.0%, up 0.3 percentage points year on year
Results for the three months of the current quarter
Q4 FY2025
Net Sales
¥38,837 million
Operating profit
¥2,131 million
Ordinary income
¥2,307 million
Net income
¥1,193 million
Full-year earnings forecast
Net Sales
¥176,000 million
Operating profit
¥11,200 million
Ordinary income
¥11,500 million
Net income
¥6,500 million net profit attributable to owners of the parent
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
FY2025 operating income year-on-year change
Impact of revenue growth+¥1.5 billion
Passing Through Price Increases+¥2.0 billion
Rationalization and mix+¥500 million
Elimination of the impact of production stoppages caused by the previous year's ransomware attack+¥500 million
Raw material prices, energy costs and other factors-¥2.4 billion
Personnel expenses, depreciation and other fixed costs-¥1.2 billion
FY2026 operating income forecast versus the previous fiscal year
Revenue Growth+¥1.5 billion
Rationalization and mix+¥1.6 billion
Foreign Exchange Effects+¥200 million
Increase in fixed costs-¥2.2 billion
Impact of the situation in the Middle East-¥900 million
Impact of material prices and other factors, and price pass-through-?億円
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The narrative discusses foreign exchange movements, material prices and other factors, demand trends, production adjustments, order recovery and higher fixed costs. Numerical assumptions are not disclosed.New initiatives
- Resource allocation focused on promising areas in the biotechnology-related business
- Expanding production capacity and stabilizing quality through the start-up of a new building at the Kanto Plant
- Operation of an ultra-wide machine for protective film
- Passing on higher material costs through pricing
Key KPIsA metric the company considers important as a management benchmark.
- Earnings per share¥106.14
- Book value per share¥1,324.14
- PBR1 times
- ROA (return on operating assets)7.1 ％
- ROIC (return on invested capital)6.8 ％
- Return on equity (ROE)8.3 ％
- Equity ratio60.5 ％
Segment results
Wellness
Net Sales
278 Hundred millions of yen+2.6%
Operating profit
-2 Hundred millions of yen
Environmental Solutions Business
Net Sales
325 Hundred millions of yen-0.4%
Operating profit
14 Hundred millions of yen+12.5%
Information & Electronics Business
Net Sales
568 Hundred millions of yen+5.3%
Operating profit
47 Hundred millions of yen+13.4%
Industrial Infrastructure Business
Net Sales
413 Hundred millions of yen+11.8%
Operating profit
50 Hundred millions of yen+22.9%
Financial targets
Actual results of ROA of 7.1%, ROIC of 6.8%, ROE of 8.3% and an equity ratio of 60.5% are presented, but target values are not disclosed.Capital expenditures
¥17,560 million FY2025 actual
Annual Dividend
Annual dividend per share¥36
Breakdown
Interim18
End of period18
Payout ratio
39.7 ％
Total payout ratio
67.5 ％
Acquisition of treasury shares
Acquisition amount¥2,584 million
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Fiscal year ending March 2026, full year |
| Net Sales | ¥158,535 million (YoY +5.2%) |
| Operating profit | ¥11,054 million (YoY +9.3%) |
| Ordinary income | ¥12,303 million (YoY +18.7%) |
| Net income | ¥7,707 million (net profit attributable to owners of the parent) (YoY +18.0%) |
| Operating profit margin | 7.0%, up 0.3 percentage points year on year |
| Results for the three months of the current quarter | Subject Q4 FY2025 / Net Sales ¥38,837 million / Operating profit ¥2,131 million / Ordinary income ¥2,307 million / Net income ¥1,193 million |
| Full-year earnings forecast | Net Sales ¥176,000 million / Operating profit ¥11,200 million / Ordinary income ¥11,500 million / Net income ¥6,500 million (net profit attributable to owners of the parent) |
| Segment results | Wellness Net Sales 278 Hundred millions of yen (YoY +2.6%) / Operating profit -2 Hundred millions of yen / Environmental Solutions Business Net Sales 325 Hundred millions of yen (YoY -0.4%) / Operating profit 14 Hundred millions of yen (YoY +12.5%) / Information & Electronics Business Net Sales 568 Hundred millions of yen (YoY +5.3%) / Operating profit 47 Hundred millions of yen (YoY +13.4%) / Industrial Infrastructure Business Net Sales 413 Hundred millions of yen (YoY +11.8%) / Operating profit 50 Hundred millions of yen (YoY +22.9%) |
| Breakdown of Factors Affecting the Change | FY2025 operating income year-on-year change Impact of revenue growth +¥1.5 billion / Passing Through Price Increases +¥2.0 billion / Rationalization and mix +¥500 million / Elimination of the impact of production stoppages caused by the previous year's ransomware attack +¥500 million / Raw material prices, energy costs and other factors -¥2.4 billion / Personnel expenses, depreciation and other fixed costs -¥1.2 billion / FY2026 operating income forecast versus the previous fiscal year Revenue Growth +¥1.5 billion / Rationalization and mix +¥1.6 billion / Foreign Exchange Effects +¥200 million / Increase in fixed costs -¥2.2 billion / Impact of the situation in the Middle East -¥900 million / Impact of material prices and other factors, and price pass-through -?億円 |
| Key KPIs | Indicator name Earnings per share / Value ¥106.14 / Year on year against the same period last year Not disclosed, Indicator name Book value per share / Value ¥1,324.14 / Year on year against the same period last year Not disclosed, Indicator name PBR / Value 1 times / Year on year against the same period last year Not disclosed, Indicator name ROA (return on operating assets) / Value 7.1 ％ / Year on year against the same period last year Not disclosed, Indicator name ROIC (return on invested capital) / Value 6.8 ％ / Year on year against the same period last year Not disclosed, Indicator name Return on equity (ROE) / Value 8.3 ％ / Year on year against the same period last year Not disclosed, Indicator name Equity ratio / Value 60.5 ％ / Year on year against the same period last year Not disclosed |
| Assumptions Underlying the Business Outlook | The narrative discusses foreign exchange movements, material prices and other factors, demand trends, production adjustments, order recovery and higher fixed costs. Numerical assumptions are not disclosed. |
| Financial targets | Actual results of ROA of 7.1%, ROIC of 6.8%, ROE of 8.3% and an equity ratio of 60.5% are presented, but target values are not disclosed. |
| Annual Dividend | Annual dividend per share ¥36 / Breakdown Interim 18 / End of period 18 |
| Payout ratio | Value 39.7 ％ / Total payout ratio 67.5 ％ |
| Acquisition of treasury shares | Acquisition amount ¥2,584 million / Number of Shares Not disclosed / Period Not disclosed |
| Capital expenditures | ¥17,560 million (FY2025 actual) |
| New initiatives | Resource allocation focused on promising areas in the biotechnology-related business, Expanding production capacity and stabilizing quality through the start-up of a new building at the Kanto Plant, Operation of an ultra-wide machine for protective film, Passing on higher material costs through pricing |
Items this document does not state (12)
Gross Profit MarginSelling, general and administrative expensesProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In FY2025, higher revenue, price pass-through, rationalization and an improved product mix, and the elimination of the impact of production stoppages caused by the ransomware attack in the previous year contributed to higher profit, while raw material prices and energy costs, personnel expenses, depreciation and other fixed costs weighed on profit. In FY2026, higher revenue and continued rationalization and mix improvement are expected, while the impact of material prices and other factors, higher fixed costs, the situation in the Middle East and foreign exchange movements are also anticipated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.